Dergiler / Retina-Vitreus / 2020 / Cilt: 29 - Sayı: 3

Evaluation of Vitreous Refl ux and Intraocular Pressure Changes in Repeated Intravitreal Injections

Sayfa
227–231
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: It was found that repeated IVI applications decreased the amount of VR and therefore increased the frequency of short-term IOP after IVI.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: To evaluate effects of repeated intravitreal injections (IVIs) on vitreous refl ux (VR) and intraocular pressure (IOP) changes in patients receiving intravitreal ranibizumab (IR) treatment.
📊
Temel Bulgular & Veri:Materials and Methods: We retrospectively reviewed fi les of patients with wet type age-related macular degeneration or diabetic macular edema patients treated with IR and demographic information0, lens status, IOP values, amount of VR and data regarding intravitreal treatment were recorded in all patients.
💡
Sonuç & Katkı:Conclusion: It was found that repeated IVI applications decreased the amount of VR and therefore increased the frequency of short-term IOP after IVI.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Purpose: To evaluate effects of repeated intravitreal injections (IVIs) on vitreous refl ux (VR) and intraocular pressure (IOP) changes in patients receiving intravitreal ranibizumab (IR) treatment. Materials and Methods: We retrospectively reviewed fi les of patients with wet type age-related macular degeneration or diabetic macular edema patients treated with IR and demographic information0, lens status, IOP values, amount of VR and data regarding intravitreal treatment were recorded in all patients. The study included 74 eyes of 74 patients who had complete data in a least 2 IVI sessions. Data obtained during the fi rst IVI session (IVI1), second IVI session (IVI2) and data from third IVE session in 14 of 74 patients were analyzed. Results: In the study populations, there were 41 female (55.6%) and the mean age was 68.61 ± 9.81 (43-81) years. The mean number of IR injections was 4.89 ± 2.79 (1-10) and mean time was 7.1 ± 3.7 months (1-24 months) between IVI1 and IVI2. IOP values before and imme- diately after IVI were signifi cantly higher in the IVI2 session, but there was no signifi cant difference in IOP values on minute 30 after IVI (p: 0.032, 0.05 for all data). Conclusion: It was found that repeated IVI applications decreased the amount of VR and therefore increased the frequency of short-term IOP after IVI.

🔖

Bu Makaleye Atıf Yap

UYAR, E., ULAŞ, F. (2020). Evaluation of Vitreous Refl ux and Intraocular Pressure Changes in Repeated Intravitreal Injections. Retina-Vitreus, Cilt: 29 - Sayı: 3, 227–231. https://ajindex.com/articles/304775

Kaynakça (15)

  1. Pang CE, Mrejen S, Hoang QV, et al. Association between Needle Size, Postinjection Refl ux, and Intraocular Pressure Spikes after Intravitreal Injections. Retina 2015;35:1401-6
  2. Saeed MU, Qureshi F, Batra R, et al. Effect of refl ux of drug during intravitreal anti-VEGF therapies on foveal thickness. Semin Ophthalmol 2011;26:61-3
  3. Doshi RR, Bakri SJ, Fung AE. Intravitreal injection tech- nique. Semin Ophthalmol 2011;26:104-13
  4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
  5. Knecht PB, Michels S, Sturm V, et al. Tunnelled versus strai- ght intravitreal injection: intraocular pressure changes, vitre- ous refl ux, and patient discomfort. Retina 2009;29:1175-81
  6. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravit- real anti-vascular endothelial growth factor therapy. Retina 2013;33:179-87
  7. Arikan G, Osman Saatci A, Hakan Oner F. Immediate intrao- cular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide. Int J Ophthalmol 2011;4:402-5
  8. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intra- ocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009;23:181-5
  9. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocu- lar pressure. J Glaucoma 2009;18:658-61
  10. Dedania VS, Bakri SJ. Sustained Elevation Of Intraocular Pressure After Intravitreal Anti-Vegf Agents: What Is the Evidence? Retina 2015;35:841-58
  11. Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Opht- halmol 2008;146:930-4 e1
  12. Kampougeris G, Spyropoulos D, Mitropoulou A. Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Pos- sible Mechanisms and Correlations. J Curr Glaucoma Pract 2013;7:19-24
  13. Boon CJ, Crama N, Klevering BJ, et al. Refl ux after intravitre- al injection of bevacizumab. Ophthalmology 2008;115:1270; author reply 1
  14. Uyar E, Ulas F, Sahin S, et al. Major factors affecting int- raocular pressure spike after intravitreal ranibizumab in- jection: Vitreous refl ux and its amount. Eur J Ophthalmol 2019;29:361-7
  15. Mojica G, Hariprasad SM, Jager RD, et al. Short-term int- raocular pressure